Jason Gerberry
Stock Analyst at B of A Securities
(3.60)
# 810
Out of 4,944 analysts
159
Total ratings
55.26%
Success rate
3.33%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $15.84 | +89.39% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $13.90 | +252.52% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $108.31 | +62.50% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $2.35 | -57.45% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $24.46 | -5.97% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $38.27 | +20.20% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $16.90 | +30.22% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $31.45 | +335.61% | 9 | Apr 1, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $10.30 | -2.91% | 3 | Feb 28, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $20.29 | +47.86% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $70.40 | +42.05% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $3.57 | +572.27% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $42.18 | +61.21% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $18.00 | +11.11% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $32.54 | -4.73% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $6.87 | +7,905.82% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $28.14 | +3.06% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $18.79 | +96.91% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $37.52 | +49.27% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $36.20 | -17.13% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $30.58 | +106.02% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $115.10 | +88.53% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $9.38 | +433.05% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $654.00 | -23.55% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.06 | +749.06% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $9.30 | +168.82% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $2.09 | +139.23% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $7.04 | +283.80% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $0.97 | +1,955.50% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $6.25 | +1,500.00% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $200.59 | -52.64% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $47.40 | +26.58% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $25.04 | +47.76% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $82.11 | +9.61% | 11 | Oct 17, 2019 |
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $15.84
Upside: +89.39%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $13.90
Upside: +252.52%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $108.31
Upside: +62.50%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.35
Upside: -57.45%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $24.46
Upside: -5.97%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $38.27
Upside: +20.20%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $16.90
Upside: +30.22%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $31.45
Upside: +335.61%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $10.30
Upside: -2.91%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $20.29
Upside: +47.86%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $70.40
Upside: +42.05%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $3.57
Upside: +572.27%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $42.18
Upside: +61.21%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $18.00
Upside: +11.11%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $32.54
Upside: -4.73%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $6.87
Upside: +7,905.82%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $28.14
Upside: +3.06%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $18.79
Upside: +96.91%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $37.52
Upside: +49.27%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $36.20
Upside: -17.13%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $30.58
Upside: +106.02%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $115.10
Upside: +88.53%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $9.38
Upside: +433.05%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $654.00
Upside: -23.55%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.06
Upside: +749.06%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $9.30
Upside: +168.82%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $2.09
Upside: +139.23%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $7.04
Upside: +283.80%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $0.97
Upside: +1,955.50%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $6.25
Upside: +1,500.00%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $200.59
Upside: -52.64%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $47.40
Upside: +26.58%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $25.04
Upside: +47.76%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $82.11
Upside: +9.61%